These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 33225706)

  • 1. Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.
    Chen H; Smaill JB; Liu T; Ding K; Lu X
    J Med Chem; 2020 Dec; 63(23):14404-14424. PubMed ID: 33225706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers.
    Pandey D; Chauhan SC; Kashyap VK; Roy KK
    Eur J Med Chem; 2024 Nov; 277():116771. PubMed ID: 39167893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting mutated GTPase KRAS in tumor therapies.
    Fan G; Lou L; Song Z; Zhang X; Xiong XF
    Eur J Med Chem; 2021 Dec; 226():113816. PubMed ID: 34520956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of RAS: proven and potential vulnerabilities.
    Zuberi M; Khan I; O'Bryan JP
    Biochem Soc Trans; 2020 Oct; 48(5):1831-1841. PubMed ID: 32869838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Kras
    Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
    J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
    Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
    Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy.
    Xu K; Park D; Magis AT; Zhang J; Zhou W; Sica GL; Ramalingam SS; Curran WJ; Deng X
    Mol Cancer; 2019 Apr; 18(1):85. PubMed ID: 30971271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From bench to bedside: current development and emerging trend of KRAS-targeted therapy.
    Chen Y; Liu QP; Xie H; Ding J
    Acta Pharmacol Sin; 2024 Apr; 45(4):686-703. PubMed ID: 38049578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.
    Nyíri K; Koppány G; Vértessy BG
    Cancer Metastasis Rev; 2020 Dec; 39(4):1091-1105. PubMed ID: 32715349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of Small Molecules That Compete with Nucleotide Binding to an Engineered Oncogenic KRAS Allele.
    Zhang Y; Larraufie MH; Musavi L; Akkiraju H; Brown LM; Stockwell BR
    Biochemistry; 2018 Feb; 57(8):1380-1389. PubMed ID: 29313669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Mutant KRAS for Anticancer Therapy.
    Chen F; Alphonse MP; Liu Y; Liu Q
    Curr Top Med Chem; 2019; 19(23):2098-2113. PubMed ID: 31475898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting cancer with small-molecule pan-KRAS degraders.
    Popow J; Farnaby W; Gollner A; Kofink C; Fischer G; Wurm M; Zollman D; Wijaya A; Mischerikow N; Hasenoehrl C; Prokofeva P; Arnhof H; Arce-Solano S; Bell S; Boeck G; Diers E; Frost AB; Goodwin-Tindall J; Karolyi-Oezguer J; Khan S; Klawatsch T; Koegl M; Kousek R; Kratochvil B; Kropatsch K; Lauber AA; McLennan R; Olt S; Peter D; Petermann O; Roessler V; Stolt-Bergner P; Strack P; Strauss E; Trainor N; Vetma V; Whitworth C; Zhong S; Quant J; Weinstabl H; Kuster B; Ettmayer P; Ciulli A
    Science; 2024 Sep; 385(6715):1338-1347. PubMed ID: 39298590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions.
    Shang Y; Fu S; Hao Q; Ying H; Wang J; Shen T
    Bioorg Chem; 2024 Mar; 144():107092. PubMed ID: 38271825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring Targeted Degradation Strategy for Oncogenic KRAS
    Zeng M; Xiong Y; Safaee N; Nowak RP; Donovan KA; Yuan CJ; Nabet B; Gero TW; Feru F; Li L; Gondi S; Ombelets LJ; Quan C; Jänne PA; Kostic M; Scott DA; Westover KD; Fischer ES; Gray NS
    Cell Chem Biol; 2020 Jan; 27(1):19-31.e6. PubMed ID: 31883964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NMR in integrated biophysical drug discovery for RAS: past, present, and future.
    Marshall CB; KleinJan F; Gebregiworgis T; Lee KY; Fang Z; Eves BJ; Liu NF; Gasmi-Seabrook GMC; Enomoto M; Ikura M
    J Biomol NMR; 2020 Nov; 74(10-11):531-554. PubMed ID: 32804298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers.
    Hyun S; Shin D
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel quinazoline-based covalent inhibitors of KRAS G12C with various cysteine-targeting warheads as potential anticancer agents.
    Li L; Zhao H; Liao H; Chen J; Liu J; Chen J
    Bioorg Chem; 2021 May; 110():104825. PubMed ID: 33774492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.
    Stites EC; Shaw AS
    CPT Pharmacometrics Syst Pharmacol; 2018 May; 7(5):342-351. PubMed ID: 29484842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Research progress on small molecule inhibitors targeting KRAS G12C with acrylamide structure and the strategies for solving KRAS inhibitor resistance.
    Jiang Z; Li Y; Zhou X; Wen J; Zheng P; Zhu W
    Bioorg Med Chem; 2024 Feb; 100():117627. PubMed ID: 38310752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS: From undruggable to a druggable Cancer Target.
    Uprety D; Adjei AA
    Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.